Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
BCRX BioCryst Pharmaceuticals	$8.39 +2.1%	$7.72	$4.11 ▼ $9.50	$1.75B	1.75	2.81 million shs	3.21 million shs
LXRX Lexicon Pharmaceuticals	$0.71 +0.7%	$0.49	$0.28 ▼ $2.45	$174.43M	1.02	6.48 million shs	8.26 million shs
SRRA Sierra Oncology	$54.99	$54.93	$14.91 ▼ $55.19	$1.34B	0.03	931,731 shs	N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BCRX BioCryst Pharmaceuticals	+2.07%	+13.38%	+7.56%	+9.82%	+99.29%
LXRX Lexicon Pharmaceuticals	+0.71%	+38.96%	+115.32%	-28.44%	-55.73%
SRRA Sierra Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	4.458 of 5 stars	4.4	2.0	0.0	4.2	3.4	1.7	0.6
LXRX Lexicon Pharmaceuticals	3.329 of 5 stars	4.2	4.0	0.0	0.0	2.6	1.7	0.6
SRRA Sierra Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	0.00	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	2.86	Moderate Buy	$15.57	85.60% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	417.60% Upside
SRRA Sierra Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LXRX, AVEO, SRRA, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00
4/10/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/28/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/7/2025	LXRX Lexicon Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $6.00
3/5/2025	LXRX Lexicon Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/4/2025	LXRX Lexicon Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$2.00 ➝ $1.00
3/3/2025	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/3/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
2/25/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $11.00
2/25/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$15.00
2/25/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
BCRX BioCryst Pharmaceuticals	$450.71M	3.89	N/A	N/A	($2.22) per share	-3.78
LXRX Lexicon Pharmaceuticals	$31.08M	5.61	N/A	N/A	$0.38 per share	1.86
SRRA Sierra Oncology	$300K	4,476.00	N/A	N/A	$6.16 per share	8.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.43	N/A	N/A	N/A	-30.01%	N/A	-24.06%	5/5/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.64	N/A	N/A	N/A	-4,109.41%	-107.38%	-64.09%	5/1/2025 (Estimated)
SRRA Sierra Oncology	-$94.66M	-$6.77	N/A	N/A	N/A	N/A	-111.88%	-100.01%	N/A

Latest LXRX, AVEO, SRRA, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	BCRX BioCryst Pharmaceuticals	-$0.07	N/A	N/A	N/A	$126.83 million	N/A
5/1/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	N/A	N/A	N/A	$1.26 million	N/A
3/6/2025	Q4 2024	LXRX Lexicon Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	$6.48 million	$26.55 million
2/24/2025	Q4 2024	BCRX BioCryst Pharmaceuticals	-$0.07	-$0.13	-$0.06	-$0.13	$126.64 million	$131.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRA Sierra Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
LXRX Lexicon Pharmaceuticals	0.56	7.45	7.43
SRRA Sierra Oncology	0.02	21.27	21.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
BCRX BioCryst Pharmaceuticals	85.88%
LXRX Lexicon Pharmaceuticals	74.70%
SRRA Sierra Oncology	99.30%

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
BCRX BioCryst Pharmaceuticals	4.80%
LXRX Lexicon Pharmaceuticals	6.80%
SRRA Sierra Oncology	44.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
BCRX BioCryst Pharmaceuticals	530	208.96 million	197.19 million	Optionable
LXRX Lexicon Pharmaceuticals	140	246.24 million	229.49 million	Optionable
SRRA Sierra Oncology	109	24.42 million	13.65 million	Optionable

LXRX, AVEO, SRRA, and BCRX Headlines

Recent News About These Companies

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

October 4, 2024 | pharmaphorum.com

New cancer treatment center breaks ground in Redding

September 25, 2024 | actionnewsnow.com

Implementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community Hospital

September 19, 2024 | ascopubs.org

New regional cancer center in Redding is called the Sierra Pacific Regional Cancer Center

August 21, 2024 | actionnewsnow.com

Sierra Space eyes IPO market as it braces for a 'profound industrial revolution' in space

April 11, 2024 | msn.com

Sierra Space, valued at $5.3 billion, eyes IPO to 'accelerate the new space economy'

April 11, 2024 | aol.com

Used 2021 GMC Sierra 2500 trucks for sale near me

April 5, 2024 | cars.com

Anemia of Inflammation

March 26, 2024 | nejm.org

Sierra Oncology Inc.

February 21, 2024 | thestreet.com

Sierra Leone Airport, Sierra Leone, Sierra Leone [ SRK / ]

February 15, 2024 | prokerala.com

2014 GMC Sierra 1500 specs & colors

February 6, 2024 | cars.com

Used 2014 GMC Sierra 1500 Denali trucks for sale near me

January 5, 2024 | cars.com

2017 GMC Sierra 1500

December 17, 2023 | motortrend.com

Safety in Radiation Oncology (SAFRON)

December 16, 2023 | iaea.org

2024 GMC Sierra 2500HD

November 24, 2023 | driving.ca

Sierra deputies believe bear mauled woman after she died

November 20, 2023 | kcra.com

Sierra Coupon for October

November 9, 2023 | time.com

Compare 6 trims on the 2021 GMC Sierra 1500

October 31, 2023 | cars.com

Clario presents a three-part webinar series on oncology trial solutions

October 31, 2023 | galvnews.com

FDA approves GSK's unique myelofibrosis treatment Ojjaara

September 18, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, AVEO, SRRA, and BCRX Company Descriptions

AVEO Pharmaceuticals NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.39 +0.17 (+2.07%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$8.32 -0.07 (-0.82%)

As of 04/25/2025 07:57 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.71 +0.01 (+0.71%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$0.71 +0.01 (+0.79%)

As of 04/25/2025 07:56 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sierra Oncology NASDAQ:SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time